Peter Rydqvist, MSc, PharmD, is present European Medical Director at Madrigal Pharmaceuticals. He graduated from Uppsala University, Uppsala/Sweden, in early 2000 and has then explored the pharmaceutical industry over the last 20+ years in various positions and ranging therapeutic areas from rare monogenetic diseases, infectious diseases, rheumatology, hematology but mainly the gastroenterology and hepatology field. He is now heading the European Medical Affairs at Madrigal with the aim together with his team to bring the Thyroid Hormone Receptor (THR)-β agonist, resmetirom, through phase 3 development and approval process in Europe for patients with NASH and fibrosis.
